Piper Sandler began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) in a research note issued on Friday, MarketBeat reports. The firm set an “overweight” rating and a $48.00 ...

While JPMorgan acknowledges TEM’s unique diagnostics-data synergy, the analysts view the stock as fully valued after its recent rally, downgrading to Neutral and raising its December 2025 price target ...